Bloomberg reports that Boston Scientific (NYSE:BSX) is considering withdrawing its high-end Synergy stent from India due to price concerns. Company representatives met with the National Pricing Authority yesterday seeking a higher price. The regulator stated that an upward revision, if approved, would not be instituted until February, however.